Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Bookmark
Investigational drug late phase More information Active drug More information Moderate burden on patient More information

Trial Details

Sponsor: M.D. Anderson Cancer Center (other)

Phase: 2

Start date: July 2, 2025

Planned enrollment: 40

Trial ID: NCT06940518
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: Ivonescimab (AK112/SMT112)

HealthScout AI Analysis

Goal: Assess whether ivonescimab monotherapy provides meaningful antitumor activity in previously treated, locally advanced or metastatic clear cell renal cell carcinoma (ccRCC), focusing on objective response and 24-week disease control per RECIST 1.1, and to characterize safety.

Patients: Adults (≥18 years) with histologically or cytologically confirmed locally advanced or metastatic ccRCC with a clear cell component, ECOG 0–2, at least one measurable lesion by RECIST 1.1, and radiographic progression on at least one prior systemic therapy that included a PD-1/PD-L1 inhibitor in the advanced/metastatic setting. Two cohorts: cohort 1 has not received prior VEGF- or HIF-2α–directed agents; cohort 2 has progressed on a prior VEGF-directed agent (HIF-2α inhibitors allowed in cohort 2). Key exclusions include uncontrolled hypertension, significant bleeding risk, recent major surgery, unstable cardiovascular disease, symptomatic or high-risk CNS metastases, active autoimmune disease requiring systemic therapy, significant infections, and pregnancy or breastfeeding.

Design: Phase 2, single-arm, nonrandomized, open-label study with two parallel experimental cohorts based on prior therapy exposure. Planned enrollment is approximately 40 participants.

Treatments: Ivonescimab administered intravenously every 3 weeks. Ivonescimab (AK112/SMT112) is a first-in-class bispecific antibody that targets PD-1 and VEGF with a tetravalent structure enabling cooperative binding; VEGF presence increases PD-1 affinity and vice versa, aiming to concurrently relieve immune suppression and inhibit angiogenesis. Early-phase studies across solid tumors have demonstrated manageable safety and antitumor activity, with an objective response rate around 25% in a phase 1a trial; in PD-L1–positive NSCLC, a phase 3 trial reported improved progression-free survival and response rate versus pembrolizumab. The molecule includes Fc-silencing mutations and a 6–7 day half-life.

Outcomes: Primary efficacy focuses on objective response rate and 24-week disease control rate per RECIST 1.1; safety will be profiled with adverse events graded by NCI CTCAE v5.0. Secondary endpoints include overall survival, progression-free survival, duration of response, and detailed adverse event characterization.

Burden on patient: Moderate. As an IV therapy given every 3 weeks, patients will require regular infusion visits, interval labs, and imaging at typical RECIST assessment frequencies; these align with standard metastatic RCC monitoring but add infusion chair time and potential on-treatment safety evaluations. No intensive pharmacokinetic sampling or mandated biopsies are described, which limits additional procedures. Travel demands are every-3-week clinic visits for infusions and periodic scans, comparable to other IV immunotherapy schedules.

Last updated: Oct 2025

Eligibility More information

chevron Show Criteria

Sites (1)

Sort by distance to:
Clear

MD Anderson Cancer Center

Houston, Texas, 77030, United States

[email protected] / 713-563-4585

Status: Recruiting

Back to trials list